BIOMAT Database Logo BIOMAT Database Logo

Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. 2018

Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy. Electronic address: tomelleri.alessandro@hsr.it.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074322 Antineoplastic Agents, Immunological Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS. Antineoplastic MAbs,Antineoplastics, Monoclonal Antibodies,Antineoplastics, Monoclonal Antibody,MAbs, Antineoplastic,Monoclonal Antibodies, Antineoplastic,Antibodies Antineoplastics, Monoclonal,Antineoplastic Monoclonal Antibodies,Immunological Antineoplastic Agents,Monoclonal Antibodies Antineoplastics,Monoclonal Antibody Antineoplastics
D000077594 Nivolumab A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA. BMS-936558,MDX-1106,ONO-4538,Opdivo,BMS 936558,BMS936558,MDX 1106,MDX1106,ONO 4538,ONO4538
D061026 Programmed Cell Death 1 Receptor An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE. PD-1 Protein,Programmed Cell Death 1 Protein,Programmed Cell Death Protein 1,Antigens, CD279,CD279 Antigen,PD-1 Receptor,PD1 Receptor,Antigen, CD279,CD279 Antigens,PD 1 Protein,PD 1 Receptor,Receptor, PD-1,Receptor, PD1
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies
D018366 Vasculitis, Leukocytoclastic, Cutaneous Disorder characterized by a vasculitic syndrome associated with exposure to an antigen such as a drug, infectious agent, or other foreign or endogenous substance. Its pathophysiology includes immune complex deposition and a wide range of skin lesions. Hypersensitivity or allergy is present in some but not all cases. Angiitis, Hypersensitivity,Cutaneous Leukocytoclastic Vasculitis,Hypersensitivity Angiitis,Hypersensitivity Vasculitis,Vasculitis, Hypersensitivity,Allergic Cutaneous Angiitis,Allergic Cutaneous Vasculitis,Angiitis, Allergic Cutaneous,Cutaneous Allergic Vasculitis,Cutaneous Leukocytoclastic Angiitis,Vasculitis, Allergic Cutaneous,Allergic Cutaneous Angiitides,Allergic Cutaneous Vasculitides,Allergic Vasculitides, Cutaneous,Allergic Vasculitis, Cutaneous,Angiitides, Allergic Cutaneous,Angiitides, Cutaneous Leukocytoclastic,Angiitides, Hypersensitivity,Angiitis, Cutaneous Leukocytoclastic,Cutaneous Allergic Vasculitides,Cutaneous Angiitides, Allergic,Cutaneous Angiitis, Allergic,Cutaneous Leukocytoclastic Angiitides,Cutaneous Leukocytoclastic Vasculitides,Cutaneous Vasculitides, Allergic,Cutaneous Vasculitis, Allergic,Hypersensitivity Angiitides,Hypersensitivity Vasculitides,Leukocytoclastic Angiitides, Cutaneous,Leukocytoclastic Angiitis, Cutaneous,Leukocytoclastic Vasculitides, Cutaneous,Leukocytoclastic Vasculitis, Cutaneous,Vasculitides, Allergic Cutaneous,Vasculitides, Cutaneous Allergic,Vasculitides, Cutaneous Leukocytoclastic,Vasculitides, Hypersensitivity,Vasculitis, Cutaneous Allergic,Vasculitis, Cutaneous Leukocytoclastic

Related Publications

Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Gallbladder vasculitis associated with cutaneous leucocytoclastic vasculitis.
November 2004, The Australasian journal of dermatology,
Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Cutaneous leucocytoclastic vasculitis associated with oxacillin.
March 2001, Diagnostic microbiology and infectious disease,
Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Cutaneous leucocytoclastic vasculitis associated with omeprazole.
February 2002, Postgraduate medical journal,
Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Cutaneous leucocytoclastic vasculitis associated with acute sarcoidosis.
August 1984, Postgraduate medical journal,
Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.
January 2008, Mycoses,
Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Apixaban-induced cutaneous leucocytoclastic vasculitis.
August 2020, BMJ case reports,
Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Cutaneous leucocytoclastic vasculitis in visceral leishmaniasis.
January 2018, Tropical doctor,
Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Cutaneous leucocytoclastic vasculitis during secukinumab treatment.
December 2021, Italian journal of dermatology and venereology,
Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Cutaneous leucocytoclastic vasculitis: a clinical and aetiological study.
October 1995, British journal of rheumatology,
Alessandro Tomelleri, and Corrado Campochiaro, and Giacomo De Luca, and Giulio Cavalli, and Lorenzo Dagna
Cutaneous leucocytoclastic vasculitis caused by cyclosporin A (Sandimmun)
April 2000, Annals of the rheumatic diseases,
Copied contents to your clipboard!